Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Practice-dependent motor cortex plasticity is reduced in non-disabled multiple sclerosis patients.
Stampanoni Bassi M, Buttari F, Maffei P, De Paolis N, Sancesario A, Gilio L, Pavone L, Pasqua G, Simonelli I, Sica F, Fantozzi R, Bellantonio P, Centonze D, Iezzi E. Stampanoni Bassi M, et al. Among authors: bellantonio p. Clin Neurophysiol. 2020 Feb;131(2):566-573. doi: 10.1016/j.clinph.2019.10.023. Epub 2019 Nov 21. Clin Neurophysiol. 2020. PMID: 31818686
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society.
Ghezzi A, Grimaldi LM, Marrosu MG, Pozzilli C, Comi G, Bertolotto A, Trojano M, Gallo P, Capra R, Centonze D, Millefiorini E, Sotgiu S, Brescia Morra V, Amato MP, Lugaresi A, Mancardi G, Caputo D, Montanari E, Provinciali L, Durelli L, Bergamaschi R, Bellantonio P, Tola MR, Cottone S, Savettieri G, Tedeschi G; MS-SIN Study Group. Ghezzi A, et al. Among authors: bellantonio p. Neurol Sci. 2011 Apr;32(2):351-8. doi: 10.1007/s10072-010-0469-0. Neurol Sci. 2011. PMID: 21234775
Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients.
Durastanti V, Lugaresi A, Bramanti P, Amato M, Bellantonio P, De Luca G, Picconi O, Fantozzi R, Locatelli L, Solda' A, Sessa E, Totaro R, Marino S, Zipoli V, Zorzon M, Millefiorini E. Durastanti V, et al. Among authors: bellantonio p. J Transl Med. 2011 Apr 18;9:42. doi: 10.1186/1479-5876-9-42. J Transl Med. 2011. PMID: 21501517 Free PMC article. Clinical Trial.
Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.
Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, Cilia S, Cottone S, Centonze D, Gasperini C; COGIMUS Study Group. Patti F, et al. Mult Scler. 2011 Aug;17(8):991-1001. doi: 10.1177/1352458511401943. Epub 2011 Apr 18. Mult Scler. 2011. PMID: 21502310 Clinical Trial.
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy.
Totaro R, Lugaresi A, Bellantonio P, Danni M, Costantino G, Gasperini C, Florio C, Pucci E, Maddestra M, Spitaleri D, Lus G, Ardito B, Farina D, Rossi M, Di Carmine C, Altobelli E, Maccarone B, Casalena A, De Luca G, Travaglini D, Di Ioia M, Di Tommaso V, Fantozzi R, Ruggieri S, Provinciali L, De Riso S, Mundi C, Fuiani A, Galgani S, Ruggieri S, Maniscalco GT, Giuliani G, Cartechini E, Petretta V, Fratta M, Alfieri G, Gatto M, Carolei A; Natalizumab Long-Term Treatment Study group. Totaro R, et al. Among authors: bellantonio p. Int J Immunopathol Pharmacol. 2014 Apr-Jun;27(2):147-54. doi: 10.1177/039463201402700201. Int J Immunopathol Pharmacol. 2014. PMID: 25004826 Free article.
Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
Prosperini L, Lucchini M, Haggiag S, Bellantonio P, Bianco A, Buscarinu MC, Buttari F, Centonze D, Cortese A, De Giglio L, Fantozzi R, Ferraro E, Fornasiero A, Francia A, Galgani S, Gasperini C, Marfia GA, Millefiorini E, Nociti V, Pontecorvo S, Pozzilli C, Ruggieri S, Salvetti M, Sgarlata E, Mirabella M. Prosperini L, et al. Among authors: bellantonio p. Neurology. 2018 Jul 10;91(2):e153-e161. doi: 10.1212/WNL.0000000000005772. Epub 2018 Jun 6. Neurology. 2018. PMID: 29875218 Clinical Trial.
Obesity worsens central inflammation and disability in multiple sclerosis.
Stampanoni Bassi M, Iezzi E, Buttari F, Gilio L, Simonelli I, Carbone F, Micillo T, De Rosa V, Sica F, Furlan R, Finardi A, Fantozzi R, Storto M, Bellantonio P, Pirollo P, Di Lemme S, Musella A, Mandolesi G, Centonze D, Matarese G. Stampanoni Bassi M, et al. Among authors: bellantonio p. Mult Scler. 2020 Sep;26(10):1237-1246. doi: 10.1177/1352458519853473. Epub 2019 Jun 4. Mult Scler. 2020. PMID: 31161863
Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients.
Stampanoni Bassi M, Drulovic J, Pekmezovic T, Iezzi E, Sica F, Gilio L, Gentile A, Musella A, Mandolesi G, Furlan R, Finardi A, Marfia GA, Bellantonio P, Fantozzi R, Centonze D, Buttari F. Stampanoni Bassi M, et al. Among authors: bellantonio p. Ther Adv Neurol Disord. 2020 Dec 8;13:1756286420970833. doi: 10.1177/1756286420970833. eCollection 2020. Ther Adv Neurol Disord. 2020. PMID: 33343708 Free PMC article.
COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab.
Buttari F, Bruno A, Dolcetti E, Azzolini F, Bellantonio P, Centonze D, Fantozzi R. Buttari F, et al. Among authors: bellantonio p. Mult Scler Relat Disord. 2021 Jul;52:102983. doi: 10.1016/j.msard.2021.102983. Epub 2021 May 4. Mult Scler Relat Disord. 2021. PMID: 33990054 Free PMC article.
44 results